BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Revumenib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Revumenib\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05360160-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Revumenib: Phase 1/2 readout est. (NCT05360160)
DESCRIPTION:Revumenib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Phase
  I-II Study Investigating the All-Oral Combination of the Menin Inhibitor 
 SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute M
 yeloid Leukemia (SAVE)\nEstimated primary completion: 1 December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/revumenib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05360160
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06284486-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Revumenib: Phase 1/2 readout est. (NCT06284486)
DESCRIPTION:Revumenib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Multi
 -Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibi
 tion of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and 
 Revumenib\nEstimated primary completion: 30 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/revumenib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06284486
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06177067-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Revumenib: Phase 1 readout est. (NCT06177067)
DESCRIPTION:Revumenib\, phase 1\, Acute Myeloid Leukemia.\nStudy: Study of 
 Revumenib\, Azacitidine\, and Venetoclax in Pediatric and Young Adult Pati
 ents With Refractory or Relapsed Acute Myeloid Leukemia\nEstimated primary
  completion: January 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/revumenib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06177067
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06222580-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Revumenib: Phase 1 readout est. (NCT06222580)
DESCRIPTION:Revumenib\, phase 1\, Acute Myeloid Leukemia.\nStudy: SNDX-5613
  and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated
  Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation\
 nEstimated primary completion: 31 January 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/revumenib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06222580
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06226571-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Revumenib: Phase 1 readout est. (NCT06226571)
DESCRIPTION:Revumenib\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Study o
 f Revumenib in Combination With Intensive Chemotherapy in Participants Wit
 h Acute Myeloid Leukemias\nEstimated primary completion: February 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/revumenib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06226571
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06313437-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20270302
DTEND;VALUE=DATE:20270303
SUMMARY:Revumenib: Phase 1 readout est. (NCT06313437)
DESCRIPTION:Revumenib\, phase 1\, Acute Myeloid Leukemia.\nStudy: Revumenib
  in Combination With 7+3 + Midostaurin in AML\nEstimated primary completio
 n: 2 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/revu
 menib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06313437
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04065399-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Revumenib: Phase 1/2 readout est. (NCT04065399)
DESCRIPTION:Revumenib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Study
  of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rear
 rangement or NPM1 Mutation\nEstimated primary completion: 15 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/revumenib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04065399
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05886049-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Revumenib: Phase 1 readout est. (NCT05886049)
DESCRIPTION:Revumenib\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Phase 1
 b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and
  Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NP
 M1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Dise
 ase\nEstimated primary completion: 31 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/revumenib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05886049
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05761171-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Revumenib: Phase 2 readout est. (NCT05761171)
DESCRIPTION:Revumenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study o
 f Revumenib in Combination With Chemotherapy for Patients Diagnosed With R
 elapsed or Refractory Leukemia\nEstimated primary completion: 31 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/revumenib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05761171
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06575296-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20280429
DTEND;VALUE=DATE:20280430
SUMMARY:Revumenib: Phase 1 readout est. (NCT06575296)
DESCRIPTION:Revumenib\, phase 1\, Acute Myeloid Leukemia.\nStudy: Revumenib
  for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell
  Transplant\nEstimated primary completion: 29 April 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/revumenib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06575296
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605949-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Revumenib: Phase 2 readout est. (NCT07605949)
DESCRIPTION:Revumenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Revumenib
 \, Azacitidine\, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML\nE
 stimated primary completion: July 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/revumenib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07605949
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07734077-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Revumenib: Phase 1/2 readout est. (NCT07734077)
DESCRIPTION:Revumenib\, phase 1/2.\nStudy: Revumenib in Patients With Myelo
 fibrosis\nEstimated primary completion: 1 December 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/revumenib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07734077
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06229912-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Revumenib: Phase 2 readout est. (NCT06229912)
DESCRIPTION:Revumenib\, phase 2.\nStudy: A Phase II Study of the Menin Inhi
 bitor Revumenib in Leukemia Associated With Upregulation of HOX Genes\nEst
 imated primary completion: 1 December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/revumenib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06229912
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07356154-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20290116
DTEND;VALUE=DATE:20290117
SUMMARY:Revumenib: Phase 1/2 readout est. (NCT07356154)
DESCRIPTION:Revumenib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Study
  of Revumenib and Mezigdomide in People With Leukemia\nEstimated primary c
 ompletion: 16 January 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/revumenib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07356154
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07211958-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Revumenib: Phase 3 readout est. (NCT07211958)
DESCRIPTION:Revumenib\, phase 3\, Acute Myeloid Leukemia.\nStudy: Study of 
 Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Ac
 ute Myeloid Leukemia (AML) With a NPM1 Mutation\nEstimated primary complet
 ion: June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/revum
 enib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07211958
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07283640-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Revumenib: Phase 1 readout est. (NCT07283640)
DESCRIPTION:Revumenib\, phase 1\, Acute Lymphoblastic Leukemia.\nStudy: A P
 hase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib f
 or Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia\nEstimated 
 primary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/revumenib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07283640
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06652438-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20291213
DTEND;VALUE=DATE:20291214
SUMMARY:Revumenib: Phase 3 readout est. (NCT06652438)
DESCRIPTION:Revumenib\, phase 3\, Acute Myeloid Leukemia.\nStudy: Revumenib
  in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or 
 KMT2A-rearranged AML\nEstimated primary completion: 13 December 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/revumenib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06652438
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686107-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Revumenib: Phase 2 readout est. (NCT07686107)
DESCRIPTION:Revumenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Trial of 
 Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory N
 UP98-rearranged AML."\nEstimated primary completion: 31 December 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/revumenib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07686107
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07949370-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Revumenib: Phase 2 readout est. (NCT07949370)
DESCRIPTION:Revumenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Phase 2
  Study of Dynamic BH3 Profiling (DBP) Guided Combination Therapy in Subjec
 ts With R/R AML\nEstimated primary completion: 31 December 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/revumenib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07949370
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923071-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Revumenib: Phase 1 readout est. (NCT07923071)
DESCRIPTION:Revumenib\, phase 1.\nStudy: A Study to Assess the Pharmacokine
 tics and Safety of Revumenib in Participants With Advanced Cancer and Hepa
 tic or Renal Impairment\nEstimated primary completion: January 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/revumenib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07923071
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636564-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20310416
DTEND;VALUE=DATE:20310417
SUMMARY:Revumenib: Phase 2 readout est. (NCT07636564)
DESCRIPTION:Revumenib\, phase 2\, Acute Lymphoblastic Leukemia.\nStudy: Tes
 ting Blinatumomab With or Without Revumenib in Patients With B-cell Acute 
 Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment\nEst
 imated primary completion: 16 April 2031. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/revumenib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07636564
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07563010-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Revumenib: Phase 2 readout est. (NCT07563010)
DESCRIPTION:Revumenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Menin-Inh
 ibitor Targeted Maintenance in AML\nEstimated primary completion: June 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/revumenib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07563010
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03013998-2841@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Revumenib: Phase 2/3 readout est. (NCT03013998)
DESCRIPTION:Revumenib\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: Study o
 f Biomarker-Based Treatment of Acute Myeloid Leukemia\nEstimated primary c
 ompletion: December 2032. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/revumenib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03013998
URL:https://assetmemo.bio/drug/revumenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
